Basil Britto Xavier

Dec 20, 2024 | genomemedicine.biomedcentral.com | MINH NGUYEN |Minh Nguyễn |Giulia De Angelis |Michael Biggel |Basil Britto Xavier |Christine Lammens | +8 more

To fulfil the study’s objectives, we analysed biobank samples collected from three wards at the Italian 1560-bed Università Cattolica Sacro Cuore hospital “Policlinico A. Gemelli” (UCSC, Rome) in a 2-year (2010–2013), multicentre, prospective, longitudinal, observational cohort study (NCT01208519), and also utilised related datasets including epidemiological and clinical data. The clinical study protocol is described elsewhere [11].

May 9, 2024 | nature.com | Basil Britto Xavier |Emmanuel Roilides |Maia De Luca |James A Berkley |Charalampos Zarras |Andrew Whitelaw | +7 more

AbstractGram-negative bacteria (GNB) are a major cause of neonatal sepsis in low- and middle-income countries (LMICs). Although the World Health Organization (WHO) reports that over 80% of these sepsis deaths could be prevented through improved treatment, the efficacy of the currently recommended first- and second-line treatment regimens for this condition is increasingly affected by high rates of drug resistance.